Abel E V, Simeone D M. Biology and clinical applications of pancreatic cancer stem cells[J]. Gastroenterology, 2013, 114(6): 1241-1248. [2]Bochatay L, Girardin M, Bichard P, et al. Pancreatic cancer in 2014: screening and epidemiology[J]. Rev Med Suisse, 2014, 10(440): 1582-1585. [3]Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29. [4]Hidalgo M. Pancreatic cancer[J]. N Engl J Med, 2010, 362(17): 1605-1617. [5]Yeo T P, Lowenfels A B. Demographics and epidemiology of pancreatic cancer[J]. Cancer J, 2012, 18(6): 477-484. [6]Wang X, Wang Y, Yu L, et al. CSPG4 in cancer: multiple roles[J]. Curr Mol Med, 2010, 10(4): 419-429. [7]Price M A, Colvin-Wanshura L E, Yang J, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma[J]. Pigment Cell Melanoma Res, 2011, 24(6): 1148-1157. [8]Huang F J, You W K, Bonaldo P, et al. Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse[J]. Dev Biol, 2010, 344(2): 1035-1046. [9]Nishiyama A, Dahlin K J, Prince J T, et al. The primary structure of NG2, a novel membrane-spanning proteoglycan[J]. J Cell Biol, 1991, 114(2): 359-371. [10]胡钰彬, 江松敏. 硫酸软骨素蛋白聚糖4在肿瘤免疫治疗中的作用[J]. 医学分子生物学杂志, 2013, 10(4): 226-232. [11]Wilson B S, Imai K, Natali P G, et al. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies[J]. Int J Cancer, 1981, 28(3): 293-300. [12]Stallcup W B. The NG2 proteoglycan: past insights and future prospects[J]. J Neurocytol, 2002, 31(6/7): 423-435. [13]Yang J, Price M A, Li G Y, et al. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition[J]. Cancer Res, 2009, 69(19): 7538-7547. [14]Hsu N C, Nien P Y, Yokoyama K K, et al. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer[J]. Biochem Biophys Res Commun, 2013, 441(2): 514-518. [15]Li C, Heidt D G, Dalerba P, et al. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67(3): 1030-1037. [16]中华医学会外科学分会胰腺外科学组, 胰腺癌诊治指南（2014版）[J]. 中华消化外科杂志, 2014, 12（11）831-837. [17]Yu L, Favoino E, Wang Y, et al. The CSPG4 specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells[J]. Immunol Res, 2011, 50(2/3): 294-302. [18]Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer[J]. J Natl Cancer Inst, 2010, 102(19): 1496-1512. [19]Rivera Z, Ferrone S, Wang X, et al. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma[J]. Clin Cancer Res, 2012, 18(19): 5352-5363. [20]Ozerdem U, Stallcup W B. Pathological angiogenesis is reduced by targeting pericytes ？via？ the NG2 proteoglycan[J]. Angiogenesis, 2004, 7(3): 269-276. [21]Poli A, Wang J, Domingues O, et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival[J]. Oncotarget, 2013, 4(9): 1527-1546.
